- Home
- EBTC vs ABVX Comparison
EBTC vs ABVX Comparison
Compare EBTC & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBTC
- ABVX
- Stock Information
- Founded
- EBTC 1989
- ABVX 2013
- Country
- EBTC United States
- ABVX France
- Employees
- EBTC N/A
- ABVX N/A
- Industry
- EBTC Major Banks
- ABVX
- Sector
- EBTC Finance
- ABVX
- Exchange
- EBTC Nasdaq
- ABVX Nasdaq
- Market Cap
- EBTC 446.9M
- ABVX 378.7M
- IPO Year
- EBTC 2005
- ABVX N/A
- Fundamental
- Price
- EBTC $35.03
- ABVX $6.40
- Analyst Decision
- EBTC
- ABVX Buy
- Analyst Count
- EBTC 0
- ABVX 8
- Target Price
- EBTC N/A
- ABVX $34.63
- AVG Volume (30 Days)
- EBTC 38.4K
- ABVX 165.7K
- Earning Date
- EBTC 04-17-2025
- ABVX 03-24-2025
- Dividend Yield
- EBTC 2.87%
- ABVX N/A
- EPS Growth
- EBTC 11.95
- ABVX N/A
- EPS
- EBTC 3.27
- ABVX N/A
- Revenue
- EBTC $172,242,000.00
- ABVX $11,172,999.00
- Revenue This Year
- EBTC N/A
- ABVX $371.31
- Revenue Next Year
- EBTC N/A
- ABVX N/A
- P/E Ratio
- EBTC $11.23
- ABVX N/A
- Revenue Growth
- EBTC 7.98
- ABVX 135.94
- 52 Week Low
- EBTC $22.60
- ABVX $4.77
- 52 Week High
- EBTC $44.41
- ABVX $16.63
- Technical
- Relative Strength Index (RSI)
- EBTC 38.16
- ABVX 52.21
- Support Level
- EBTC $33.15
- ABVX $5.89
- Resistance Level
- EBTC $35.14
- ABVX $6.71
- Average True Range (ATR)
- EBTC 1.50
- ABVX 0.60
- MACD
- EBTC -0.07
- ABVX 0.08
- Stochastic Oscillator
- EBTC 34.55
- ABVX 84.02
About EBTC Enterprise Bancorp Inc
Enterprise Bancorp Inc is a holding company engaged in the business of gathering deposits from the general public and investing in loans and investment securities. Through the Bank and its subsidiaries, the company offers a range of commercial, residential, and consumer loan products, deposit products, and cash management services, as well as wealth management and wealth services.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.